<DOC>
	<DOCNO>NCT02635360</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness immunotherapy combination chemotherapy radiation ( chemoradiation ) treatment advanced cervical cancer . Pembrolizumab , type immunotherapy call checkpoint inhibitor , administer chemoradiation .</brief_summary>
	<brief_title>Pembrolizumab Chemoradiation Treatment Advanced Cervical Cancer</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Confirmed cervical cancer . Must adequate organ function . Subject pregnant . Recurrent cervical cancer . Distant metastasis . Malignancy within last 5 year ; basal cell carcinoma squamous cell carcinoma skin undergone potentially curative therapy permissable . Subject prior radiation , chemotherapy , target therapy , investigational therapy cervical cancer . Subject immunodeficiency . Known history HIV , Hepatitis B , Hepatitis C , TB , inflammatory bowel disease . Hypersensitivity pembrolizumab similar drug . Subject active autoimmune disease past 2 year . Known history noninfectious pneumonitis . Subject active infection . Subject know active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Subjects previously treat brain metastasis permissible . Talk Study Contact specific .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>advanced</keyword>
	<keyword>cervical cancer</keyword>
	<keyword>pembrolizumab</keyword>
	<keyword>chemoradiation</keyword>
	<keyword>immunotherapy</keyword>
</DOC>